Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Nine Tar Heels Pick Up CSC At-Large Academic All-District Honors
Each year, the College Sports Communicators organization highlights student-athletes from across the country for their performances in competition and in the classroom. In the at-large...
Tue Jun 16, 2026

Cure Innovation Index ranks Carolina 5th among publics, 18th overall
The University of North Carolina ranked 18th among U.S. universities and fifth among publics in the inaugural Cure Innovation Index. The comprehensive new assessment measures...
Mon Jun 15, 2026

Carrburritos Announces Move to Former Elmo’s Diner Location in Carr Mill Mall
A Carrboro staple is making a big move after nearly 30 years in business. Carrburritos, a popular burrito restaurant, will take over the Carr Mill...
Sun Jun 14, 2026

Aer Lingus College Football Classic 2026: Much More Than A Game
The University of North Carolina will host or participate in business, cultural, academic, athletic, and arts events in Dublin, Ireland, the week leading up to...
Thu Jun 11, 2026